Log In
BCIQ
Print this Print this
 

Curosurf, poractant alfa

  Manage Alerts
Collapse Summary General Information
Company Chiesi Farmaceutici S.p.A.
DescriptionPoractant alpha
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic
Latest Stage of DevelopmentMarketed
Standard IndicationRespiratory distress syndrome (RDS)
Indication DetailsTreat respiratory distress syndrome (RDS) in premature infants
Regulatory Designation
PartnerEmerge Health Pty. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$205.3M

$205.3M

0


 Deals Details
Get a free BioCentury trial today